Press releaseGlobe Newswire
Ernexa Therapeutics
ERNA · NASDAQ
$2.24+$0.26 (+13.13%)TodayMarket closed ·
Prev close $1.98
Latest news
- Press releaseGlobe Newswire
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
- Press releaseGlobe Newswire
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
- Press releaseGlobe Newswire
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
- Press releaseGlobe Newswire
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
- NewsVandana Singh
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
- Press releaseGlobe Newswire
Three Biotechs Deliver Catalysts to Watch
- NewsAvi Kapoor
Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views
- Press releaseGlobe Newswire
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
- News
Ernexa Therapeutics Advances ERNA-101 Toward IND Filing In Q3 2026; Targeting Phase 1 Cancer Trial Initiation In Q4 2026
- Press releaseGlobe Newswire
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsEvette Mitkov
Ernexa Stock Is Jumping Today: What's Going On?
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Nasdaq Dips Over 1%; US Inflation Surges To 3.8% In April
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsDylan Berman
Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data
- News
Ernexa Therapeutics ERNA-101 Shows Durable Tumor Regression With PD-1 Blockade In Preclinical Ovarian Cancer Models; IND Submission Planned Q3 2026; First-In-Human Trial Expected Q4 2026
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Nasdaq Jumps Over 400 Points; AutoNation Shares Surge Following Q4 Earnings
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Dow Jumps Over 600 Points; Amazon Shares Dip After Q4 Results
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releasePRNewswire
/C O R R E C T I O N -- Cellipont Bioservices/
- Press releasePRNewswire
Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer
- NewsAvi Kapoor
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.